(A Top Pick Jan 30/20, Up 18%) Continues to buy. Growth from emerging markets over the next 10 years is quite strong. Normalization of activity will bring revenue to pre-pandemic levels by 2022. Diversified.

(A Top Pick Jan 30/20, Down 1%) Still likes. Continues to buy. Discount to other big pharma. Cancer drugs are very high margin. Pandemic has spurred pharma sales. Will benefit as life returns to normal. Yield is 3.1%.

(A Top Pick Jan 30/20, Up 20%) Revenue has responded well to pandemic. Digital initiatives acting very well. Pay a premium at 36x forward earnings for 15% growth. Strong, iconic name. Cautious on buying going forward, based on valuation.

Down about 30%. Buying opportunity. Long-term secular e-commerce growth. Middle class growth provides a runway of increased earnings. Trading at 20x earnings for 20% growth. No dividend. (Analysts’ price target is $331.03)

Premier shopping mall in the US. Unique shopping experiences. Post-Covid, the outlook is impressive. Yield is 5.99%. (Analysts’ price target is $96.47)